NCT03221621: HS-COST

Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS

Status unknown Phase 4 Last updated 8 February 2019

What this trial tests

Phase 4 trial testing Wide Excision in Hidradenitis Suppurativa in 128 participants. Status unknown.

Timeline

31 July 2018

Primary endpoint
31 July 2022

31 July 2022

Quick facts

Lead sponsor	Erasmus Medical Center
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	128
Start date	31 July 2018
Primary completion	31 July 2022
Estimated completion	31 July 2022
Sites	1 location across Netherlands

Drugs / interventions tested

• Wide Excision
• Adalimumab Injection

Conditions studied

• Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

Erasmus Medical Center

Who can join

18 and older, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this randomized controlled clinical trial in a real life setting is to evaluate the cost-utility of limumab monotherapy compared with the combination of adalimumab and a maximum of three surgeries after two years of treatment in adult patients with moderate to severe HS.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Hidradenitis Suppurativa: Where We Are and Where We Are Going.
   Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, et al · · 2021 · cited 85× · PMID 34440863 · DOI 10.3390/cells10082094
2. Insights into the Pathogenesis of HS and Therapeutical Approaches.
   Rosi E, Fastame MT, Scandagli I, Di Cesare A, et al · · 2021 · cited 27× · PMID 34572354 · DOI 10.3390/biomedicines9091168